AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27237081 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to eBI
Number of subjects: 120
Study 25706053 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 46
Study 25706053 — intervention group
Group type: COMPARATOR
Intervention: Placebo-KT
Number of subjects: 46
Study 23801606 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Switch (IS) to raltegravir
Number of subjects: 164
Study 23801606 — intervention group
Group type: COMPARATOR
Intervention: Deferred Switch (DS) to raltegravir at week 24
Number of subjects: 164
Study 21083623 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP‐ACFP paste
Number of subjects: 54
Study 21083623 — intervention group
Group type: COMPARATOR
Intervention: Control paste
Number of subjects: 54
Study 18502772 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthonasal stimulation
Number of subjects: 30
Study 18502772 — intervention group
Group type: EXPERIMENTAL
Intervention: Retronasal stimulation
Number of subjects: 30
Study 18502772 — intervention group
Group type: COMPARATOR
Intervention: Comparison of stimulation routes
Number of subjects: 30
Study 16421364 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 percent hypertonic saline
Number of subjects: 164
Study 16421364 — intervention group
Group type: COMPARATOR
Intervention: 0.9 percent saline (control)
Number of subjects: 164
Study 14656276 — intervention group
Group type: EXPERIMENTAL
Intervention: TEC (paclitaxel 175 mg/m2, carboplatin AUC 5, epirubicin 75 mg/m2)
Number of subjects: 887
Study 14656276 — intervention group
Group type: COMPARATOR
Intervention: TC (paclitaxel 175 mg/m2, carboplatin AUC 5)
Number of subjects: 887
Study 14656276 — intervention group
Group type: EXPERIMENTAL
Intervention: TEC
Number of subjects: 887
Study 10843145 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycemic hyperinsulinemic clamp (3 mU/kg x min)
Number of subjects: 12
Study 10843145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9002786 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Plak Remover (D7)
Number of subjects: 49
Study 9002786 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Plak Control (D9)
Number of subjects: 49
Study 9002786 — intervention group
Group type: COMPARATOR
Intervention: Sonicare
Number of subjects: 49
Study 8402762 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (300 mg/day)
Number of subjects: 21
Study 8402762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 3805311 — intervention group
Group type: EXPERIMENTAL
Intervention: Paradoxical intention
Number of subjects: 0
Study 3805311 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus control
Number of subjects: 0
Study 3805311 — intervention group
Group type: COMPARATOR
Intervention: Information
Number of subjects: 0
Study 3805311 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31960175 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based SAD-specific group cognitive behavioral therapy (CBT), n=31
Number of subjects: 67
Study 31960175 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC), n=36
Number of subjects: 67
Study 31960175 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT group
Number of subjects: 67
Study 30367021 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiography and 2-dimensional echocardiography
Number of subjects: 60
Study 27737602 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Group (ExG) - 16-week exercise training program combining aerobic activities and resistance training
Number of subjects: 32
Study 27737602 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Group (ExG)
Number of subjects: 32
Study 27737602 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 32
Study 24281236 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg once daily at bedtime
Number of subjects: 468
Study 24281236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study 20216118 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine therapy
Number of subjects: 37
Study 18380934 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation programme (n = 52)
Number of subjects: 104
Study 18380934 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based rehabilitation programme (n = 52)
Number of subjects: 104
Study 15984576 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 64
Study 15984576 — intervention group
Group type: COMPARATOR
Intervention: No thrombolytic therapy
Number of subjects: 64
Study 15984576 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenoblockers (administered in both groups)
Number of subjects: 64
Study 12753444 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of morphine (40 micro g x kg‐1 initial bolus, 10 micro g.ml‐1 infusion)
Number of subjects: 26
Study 12753444 — intervention group
Group type: COMPARATOR
Intervention: Epidural infusion of clonidine (1 micro g x kg‐1 initial bolus, 0.6 micro g.ml‐1 infusion)
Number of subjects: 26
Study 10069510 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (once daily inhalation for 28 days)
Number of subjects: 0
Study 10069510 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (protection against methacholine challenge)
Number of subjects: 0
Study 10069510 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (compared to baseline)
Number of subjects: 0
Study 8913544 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily
Number of subjects: 122
Study 8913544 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg once daily
Number of subjects: 122
Study 8913544 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg twice daily
Number of subjects: 122
Study 8913544 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan with low-dose hydrochlorothiazide
Number of subjects: 122
Study 8913544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 1857312 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental prosthesis (Snore‐No‐More) worn on experimental nights
Number of subjects: 14
Study 1857312 — intervention group
Group type: COMPARATOR
Intervention: No device worn on control nights
Number of subjects: 14
Study 6298934 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of cotrimoxazole
Number of subjects: 68
Study 6298934 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of amoxycillin
Number of subjects: 68
Study 6298934 — intervention group
Group type: COMPARATOR
Intervention: Oral dose of Na-bicarbonate
Number of subjects: 68
Study 30203839 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab (anti-IL6 monoclonal antibody)
Number of subjects: 38
Study 29851741 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week multicomponent intervention (n=48)
Number of subjects: 89
Study 29851741 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 89
Study 26067580 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaching training group (n = 15) received 3 sessions of training by a physical therapist
Number of subjects: 30
Study 26067580 — intervention group
Group type: COMPARATOR
Intervention: Social control group (n = 15) received a similar amount of time sitting in the therapist's lap
Number of subjects: 30
Study 23336746 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin cream (0.05%) and Aloe vera topical gel (50%)
Number of subjects: 60
Study 23336746 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin cream (0.05%) and vehicle
Number of subjects: 60
Study 22250951 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial stent placement with Gateway balloon and Wingspan self‐expanding nitinol stent
Number of subjects: 0
Study 22250951 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial angioplasty and stent placement
Number of subjects: 0
Study 22250951 — intervention group
Group type: EXPERIMENTAL
Intervention: Credentialing process for interventionalists
Number of subjects: 0
Study 20938821 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 0
Study 20938821 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic reflux correction
Number of subjects: 0
Study 20938821 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance
Number of subjects: 0
Study 20938821 — intervention group
Group type: EXPERIMENTAL
Intervention: Open operative reflux therapy
Number of subjects: 0
Study 18547426 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline-stabilized orthosilicic acid (ch-OSA) 6 mg Si
Number of subjects: 136
Study 18547426 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline-stabilized orthosilicic acid (ch-OSA) 12 mg Si
Number of subjects: 136
Study 18547426 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline-stabilized orthosilicic acid (ch-OSA) 3 mg Si
Number of subjects: 136
Study 18547426 — intervention group
Group type: COMPARATOR
Intervention: Calcium and Vitamin D3 (Ca/Vit D3) alone
Number of subjects: 136
Study 18547426 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline-stabilized orthosilicic acid (ch-OSA)
Number of subjects: 136
Study 18547426 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline-stabilized orthosilicic acid (ch-OSA) 6 mg Si (subgroup analysis)
Number of subjects: 136
Study 15947831 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% polyvinylpyrrolidone-iodine solution
Number of subjects: 30
Study 15947831 — intervention group
Group type: COMPARATOR
Intervention: 0.9% physiological saline solution
Number of subjects: 30
Study 12199971 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurized metered-dose inhalers (MDIs)
Number of subjects: 10
Study 12199971 — intervention group
Group type: COMPARATOR
Intervention: Dry powder inhalers (DPIs)
Number of subjects: 10
Study 12199971 — intervention group
Group type: COMPARATOR
Intervention: Turbuhaler (DPI)
Number of subjects: 10
Study 12199971 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI
Number of subjects: 10
Study 10424324 — intervention group
Group type: COMPARATOR
Intervention: Desmopressin alone (reference)
Number of subjects: 18
Study 10424324 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (4 mg at -24, -12 h and -1 h)
Number of subjects: 18
Study 10424324 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (250 mg q.i.d, first dose 3 days before study)
Number of subjects: 18
Study 8524984 — intervention group
Group type: EXPERIMENTAL
Intervention: ipsapirone (0.3 mg per kg body weight)
Number of subjects: 30
Study 2273527 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (1.0 mg FTC‐estimated nicotine delivery)
Number of subjects: 30
Study 2273527 — intervention group
Group type: COMPARATOR
Intervention: Nicotine-free cigarette
Number of subjects: 30
Study 7006783 — intervention group
Group type: EXPERIMENTAL
Intervention: Different types of therapy for five types of glomerulonephritis (specific therapies not detailed in the abstract)
Number of subjects: 0
Study 31879033 — intervention group
Group type: EXPERIMENTAL
Intervention: SYDNEY device (1 × 300 mg injection)
Number of subjects: 69
Study 31879033 — intervention group
Group type: COMPARATOR
Intervention: Currently approved autoinjector (2 × 150 mg injections)
Number of subjects: 69
Study 31879033 — intervention group
Group type: EXPERIMENTAL
Intervention: SYDNEY device
Number of subjects: 69
Study 31879033 — intervention group
Group type: COMPARATOR
Intervention: Currently approved autoinjector
Number of subjects: 69
Study 30531304 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 37
Study 30531304 — intervention group
Group type: EXPERIMENTAL
Intervention: m.10398G mtDNA variant
Number of subjects: 37
Study 27005768 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 0
Study 27005768 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 25935581 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 4038
Study 24085466 — intervention group
Group type: EXPERIMENTAL
Intervention: PICSI (sperm selected based on ability to bind to hyaluronic acid)
Number of subjects: 156
Study 24085466 — intervention group
Group type: COMPARATOR
Intervention: ICSI (sperm selected based on visual assessment)
Number of subjects: 156
Study 20934265 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality treatment (CMT) using radiotherapy (RT), infusional 5‐fluorouracil, and mitomycin C
Number of subjects: 577
Study 20934265 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (EBRT) boost (15 Gy)
Number of subjects: 577
Study 20934265 — intervention group
Group type: EXPERIMENTAL
Intervention: Iridium-192 implant boost (25 Gy)
Number of subjects: 577
Study 20934265 — intervention group
Group type: EXPERIMENTAL
Intervention: Boosted patients
Number of subjects: 577
Study 20934265 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 577
Study 19106078 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions specifying motivational cues
Number of subjects: 0
Study 19106078 — intervention group
Group type: COMPARATOR
Intervention: Implementation intentions specifying situational cues
Number of subjects: 0
Study 17364418 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Substance Abuse Domestic Violence (SADV) group
Number of subjects: 85
Study 17364418 — intervention group
Group type: COMPARATOR
Intervention: Twelve-Step Facilitation (TSF) Group
Number of subjects: 85
Study 15188832 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg danazol three times daily for 6 months
Number of subjects: 100
Study 15188832 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg leuprorelin acetate depot every 28 days for 6 months
Number of subjects: 100
Study 15188832 — intervention group
Group type: COMPARATOR
Intervention: Control group (women without pelvic disease)
Number of subjects: 100
Study 11469429 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol test (20 patients)
Number of subjects: 133
Study 11469429 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin test (23 patients)
Number of subjects: 133
Study 11469429 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin test (positive group)
Number of subjects: 133
Study 11469429 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol test (positive group)
Number of subjects: 133
Study 11469429 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 133
Study 11469429 — intervention group
Group type: COMPARATOR
Intervention: Negative response group
Number of subjects: 133
Study 9521833 — intervention group
Group type: EXPERIMENTAL
Intervention: Nightcap sleep monitor
Number of subjects: 0
Study 9521833 — intervention group
Group type: EXPERIMENTAL
Intervention: Awakenings after 15 s to 5 min of sleep
Number of subjects: 0
Study 9521833 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-onset reports
Number of subjects: 0
Study 8110557 — intervention group
Group type: EXPERIMENTAL
Intervention: dobutamine 10 micrograms kg‐1 min‐1 before discontinuation of CPB
Number of subjects: 28
Study 8110557 — intervention group
Group type: COMPARATOR
Intervention: enoximone 0.5 mg kg‐1 followed by an infusion of 10 micrograms kg‐1 min‐1 before discontinuation of CPB
Number of subjects: 28
Study 2922790 — intervention group
Group type: EXPERIMENTAL
Intervention: Neocyte-enriched RBCs
Number of subjects: 0
Study 2922790 — intervention group
Group type: COMPARATOR
Intervention: Control RBCs of all ages
Number of subjects: 0
Study 20034163 — intervention group
Group type: EXPERIMENTAL
Intervention: Secobarbital
Number of subjects: 0
Study 20034163 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0
Study 20034163 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 0
Study 20034163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20034163 — intervention group
Group type: EXPERIMENTAL
Intervention: One second estimation schedule
Number of subjects: 0
Study 20034163 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten second estimation schedule
Number of subjects: 0
Study 30876959 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-step approach using NAFLD fibrosis score (NFS) followed by liver stiffness measurement (LSM) for patients with indeterminate or high NFS
Number of subjects: 759
Study 30876959 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-step approach using NAFLD fibrosis score (NFS) followed by LSM
Number of subjects: 759
Study 30876959 — intervention group
Group type: EXPERIMENTAL
Intervention: LSM ≥10 kPa alone for diagnosis of advanced fibrosis
Number of subjects: 759
Study 30876959 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrosis-4 score
Number of subjects: 759
Study 28320794 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health volunteers (CHVs) offering free rapid diagnostic tests (RDTs) and vouchers for WHO-qualified artemisinin combination therapy (ACT) at a reduced price.
Number of subjects: 0
Study 28320794 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 0
Study 26143613 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized-SC
Number of subjects: 524
Study 26143613 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-SC
Number of subjects: 524
Study 26143613 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-ID
Number of subjects: 524
Study 23551657 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg twice a day for 14 days)
Number of subjects: 44
Study 23551657 — intervention group
Group type: COMPARATOR
Intervention: Control (standard medical treatment for ICH)
Number of subjects: 44
Study 21450118 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 × 240 ml black tea providing 168 mg of caffeine
Number of subjects: 21
Study 21450118 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 × 240 ml black tea providing 252 mg of caffeine
Number of subjects: 21
Study 21450118 — intervention group
Group type: COMPARATOR
Intervention: Boiled water (control)
Number of subjects: 21
Study 19084784 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based game
Number of subjects: 0
Study 19084784 — intervention group
Group type: COMPARATOR
Intervention: Self-study computerized flash cards
Number of subjects: 0
Study 17473069 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose L‐T4 (subclinical hypothyroid arm)
Number of subjects: 19
Study 17473069 — intervention group
Group type: COMPARATOR
Intervention: Usual dose L‐T4 (euthyroid arm)
Number of subjects: 19
Study 15033503 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback framing positive social cues
Number of subjects: 64
Study 15033503 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback framing absence of negative outcomes
Number of subjects: 64
Study 11392571 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate Diskus inhaler
Number of subjects: 0
Study 11392571 — intervention group
Group type: COMPARATOR
Intervention: Budesonide Turbuhaler inhaler
Number of subjects: 0
Study 11392571 — intervention group
Group type: EXPERIMENTAL
Intervention: Diskus inhaler
Number of subjects: 0
Study 9677446 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative radiation therapy followed by cystectomy
Number of subjects: 0
Study 9677446 — intervention group
Group type: COMPARATOR
Intervention: Cystectomy alone
Number of subjects: 0
Study 7932278 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam treatment over 8 weeks
Number of subjects: 2
Study 7932278 — intervention group
Group type: COMPARATOR
Intervention: Normal women in the premenstrual phase
Number of subjects: 2
Study 3051870 — intervention group
Group type: EXPERIMENTAL
Intervention: Vabra mc cervix
Number of subjects: 298
Study 3051870 — intervention group
Group type: COMPARATOR
Intervention: Conventional curettage
Number of subjects: 298
Study 29024081 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosa canina fruit capsules (500 mg, twice daily for 20 days)
Number of subjects: 400
Study 29024081 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 400
Study 27138026 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC1 (amlodipine/rosuvastatin 10mg/20mg)
Number of subjects: 24
Study 27138026 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC2 (amlodipine/rosuvastatin 10mg/20mg)
Number of subjects: 24
Study 27138026 — intervention group
Group type: COMPARATOR
Intervention: Reference tablets (coadministered commercially available amlodipine and rosuvastatin)
Number of subjects: 24
Study 23959379 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopic guidance
Number of subjects: 609
Study 23959379 — intervention group
Group type: COMPARATOR
Intervention: Anatomic method
Number of subjects: 609
Study 23959379 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 609
Study 22639864 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-rigid ankle brace
Number of subjects: 100
Study 22639864 — intervention group
Group type: COMPARATOR
Intervention: Tape
Number of subjects: 100
Study 20416041 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index carbohydrate diet
Number of subjects: 0
Study 20416041 — intervention group
Group type: COMPARATOR
Intervention: No dietary intervention
Number of subjects: 0
Study 20664147 — intervention group
Group type: EXPERIMENTAL
Intervention: WHEE (the wholistic hybrid derived from EMDR and EFT), n=50
Number of subjects: 91
Study 20664147 — intervention group
Group type: COMPARATOR
Intervention: Control group (beyond the 15‐ to 18‐foot range of the healer's EM heart field), n=41
Number of subjects: 91
Study 15844319 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) injection (10 microg/d for 10 days in one month, for a total of 6 months)
Number of subjects: 24
Study 15844319 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) injection
Number of subjects: 24
Study 15844319 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PGE1, same other therapy)
Number of subjects: 24
Study 12236411 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation Responsive to Family (PERF) model
Number of subjects: 19
Study 12236411 — intervention group
Group type: COMPARATOR
Intervention: Usual services
Number of subjects: 19
Study 10403876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral palsy not taking anticonvulsant medication
Number of subjects: 29